[
    [
        {
            "time": "",
            "orginal_text": "“痔疮一哥”马应龙跨界卖口红 美容真的不分上下？",
            "features": {
                "keywords": [
                    "马应龙",
                    "跨界",
                    "口红",
                    "美容"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "消费"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "“痔疮一哥”马应龙跨界卖口红 美容真的不分上下？",
            "scores": {
                "News_content": "“痔疮一哥”马应龙跨界卖口红 美容真的不分上下？",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "医药生物行业2019年中报业绩前瞻:医药板块持续分化，寻找景气与避险的交集",
            "features": {
                "keywords": [
                    "医药生物",
                    "2019年中报",
                    "业绩前瞻",
                    "板块分化",
                    "景气",
                    "避险"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "医药生物行业2019年中报业绩前瞻:医药板块持续分化，寻找景气与避险的交集",
            "scores": {
                "News_content": "医药生物行业2019年中报业绩前瞻:医药板块持续分化，寻找景气与避险的交集",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        }
    ]
]